Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

International Journal of Molecular Sciences

Volumn 15, Issue 12, 2014, Pages 23024-23041

  Kristensen, Tina BøGelund ^a   Knutsson, Malin L T ^a   Wehland, Markus ^b   Laursen, Britt Elmedal ^c   Grimm, Daniela ^a   Warnke, Elisabeth ^b   Magnusson, Nils E ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anti angiogenic therapy; Biomarkers; Breast cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERIBULIN; ETOPOSIDE; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; LURBINECTEDIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAMUCIRUMAB; SORAFENIB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; BLOOD VESSEL PERMEABILITY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; GENE EXPRESSION REGULATION; HUMAN; HYPERTENSION; INTUSSUSCEPTION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL (TOPIC); FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOMARKERS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84916918721     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151223024     Document Type: Article

References (62)

1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available online: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed on 1 December 2014).
2. Grimm, D.; Wehland, M.; Pietsch, J.; Infanger, M.; Bauer, J. Drugs interfering with apoptosis in breast cancer. Curr. Pharm. Des. 2011, 17, 272-283.
3. Grimm, D.; Bauer, J.; Schönberger, J. Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and its metastases. Curr. Vasc. Pharmacol. 2009, 7, 347-357.
4. Miklos, G.L. Bevacizumab in neoadjuvant treatment for breast cancer. N. Engl. J. Med. 2012, 366, 1637-1640.
5. Bear, H.D.; Tang, G.; Rastogi, P.; Geyer, C.E., Jr; Robidoux, A.; Atkins, J.N.; Baez-Diaz, L.; Brufsky, A.M.; Mehta, R.S.; Fehrenbacher, L.; et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 2012, 366, 310-320.
6. Fan, F.; Schimming, A.; Jaeger, D.; Podar, K. Targeting the tumor microenvironment: Focus on angiogenesis. J. Oncol. 2012, 2012, 281-261, doi:10.1155/2012/281261.
7. Jelkmann, W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin. Chem. 2001, 47, 617-623.
8. Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473, 298-307.
9. Claesson-Welsh, L.; Welsh, M. VEGFA and tumour angiogenesis. J. Intern. Med. 2013, 273, 114-127.
10. Wehland, M.; Bauer, J.; Magnusson, N.E.; Infanger, M.; Grimm, D. Biomarkers for anti-angiogenic therapy in cancer. Int. J. Mol. Sci. 2013, 14, 9338-9364.
11. Leite de Oliveira, R.; Hamm, A.; Mazzone, M. Growing tumor vessels: More than one way to skin a cat—Implications for angiogenesis targeted cancer therapies. Mol. Aspects Med. 2011, 32, 71-87.
12. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
13. Niu, G.; Chen, X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.Curr. Drug Targets 2010, 11, 1000-1017.
14. Leenders, W.P.; Kusters, B.; de Waal, R.M. Vessel co-option: How tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002, 9, 83-87.
15. Donnem, T.; Hu, J.; Ferguson, M.; Adighibe, O.; Snell, C.; Harris, A.L.; Gatter, K.C.; Pezzella, F. Vessel co-option in primary human tumors and metastases: An obstacle to effective anti-angiogenic treatment? Cancer Med. 2013, 2, 427-436.
16. Ferrara, N. The role of VEGF in the regulation of physiological and pathological angiogenesis. In Mechanisms of Angiogenesis; Clauss, M., Breier, G., Eds.; Birkhäuser: Basel, Switzerland, 2005; pp. 209-231.
17. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004, 25, 581-611.
18. Grimm, D.; Bauer, J.; Ulbrich, C.; Westphal, K.; Wehland, M.; Infanger, M.; Aleshcheva, G.; Pietsch, J.; Gardi, M.; Beck, M.; et al. Different responsiveness of endothelial cells to Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor added to culture media under gravity and simulated microgravity. Tissue Eng. Part A 2010, 16, 1559-1573.
19. Infanger, M.; Grosse, J.; Westphal, K.; Leder, A.; Ulbrich, C.; Paul, M.; Grimm, D. Vascular Endothelial Growth Factor induces extracellular matrix proteins and osteopontin in the umbilical artery. Ann. Vasc. Surg. 2008, 22, 273-284.
20. Infanger, M.; Faramarzi, S.; Grosse, J.; Kurth, E.; Ulbrich, C.; Bauer, J.; Wehland, M.; Kreutz, R.; Kossmehl, P.; Paul, M.; et al. Expression of Vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia-reperfusion injury. Cardiovasc. Pathol. 2007, 16, 291-299.
21. Infanger, M.; Shakibaei, M.; Kossmehl, P.; Hollenberg, S.M.; Grosse, J.; Faramarzi, S.; Schulze-Tanzil, G.; Paul, M.; Grimm, D. Intraluminal application of VEGF enhances healing of microvascular anastomosis in a rat model. J. Vasc. Res. 2005, 42, 202-213.
22. Infanger, M.; Schmidt, O.; Kossmehl, P.; Grad, S.; Ertel, W.; Grimm, D. Vascular endothelial growth factor serum level is strongly enhanced after burn injury and correlated with local and general tissue edema. Burns 2004, 30, 305-311.
23. Grothey, A.; Ellis, L.M. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 2008, 14, 170-177.
24. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8, 592-603.
25. Miller, K.D.; Chap, L.I.; Holmes, F.A.; Cobleigh, M.A.; Marcom, P.K.; Fehrenbacher, L.; Dickler, M.; Overmoyer, B.A.; Reimann, J.D.; Sing, A.P.; et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005, 23, 792-799.
26. Mackey, J.; Gelmon, K.; Martin, M.; McCarthy, N.; Pinter, T.; Rupin, M.; Youssoufian, H. TRIO-012: A multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel vs. placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin. Breast Cancer 2009, 9, 258-261.
27. Wehland, M.; Bauer, J.; Infanger, M.; Grimm, D. Target-based anti-angiogenic therapy in breast cancer. Curr. Pharm. Des. 2012, 18, 4244-4257.
28. Von Minckwitz, G.; Eidtmann, H.; Rezai, M.; Fasching, P.A.; Tesch, H.; Eggemann, H.; Schrader, I.; Kittel, K.; Hanusch, C.; Kreienberg, R.; et al. Neoadjuvant chemotherapy and bevacizumab for her2-negative breast cancer. N. Engl. J. Med. 2012, 366, 299-309.
29. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab vs. paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357, 2666-2676.
30. Refaat, T.; Choi, M.; Gaber, G.; Kiel, K.; Mehta, M.; Gradishar, W.; Small, W. Markov model and cost-effectiveness analysis of bevacizumab in her2-negative metastatic breast cancer. Am. J. Clin. Oncol. 2014, 37, 480-485.
31. Miles, D.W.; Diéras, V.; Cortés, J.; Duenne, A.A.; Yi, J.; O’Shaughnessy, J. First-line bevacizumab in combination with chemotherapy for her2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients. Ann. Oncol. 2013, 24, 2773-2780.
32. Robert, N.J.; Dieras, V.; Glaspy, J.; Brufsky, A.M.; Bondarenko, I.; Lipatov, O.N.; Perez, E.A.; Yardley, D.A.; Chan, S.Y.; Zhou, X.; et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase iii trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 2011, 29, 1252-1260.
33. Gligorov, J.; Doval, D.; Bines, J.; Alba, E.; Cortes, P.; Pierga, J.Y.; Gupta, V.; Costa, R.; Srock, S.; Ducla, S.; et al. Maintenance capecitabine and bevacizumab vs. bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with her2-negative metastatic breast cancer (imelda): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15, 1351-1360.
34. Brufsky, A.M.; Hurvitz, S.; Perez, E.; Swamy, R.; Valero, V.; O’Neill, V.; Rugo, H.S. RIBBON-2: A randomized, double-blind, placebo-controlled, phase iii trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2011, 29, 4286-4293.
35. Von Minckwitz, G.; Puglisi, F.; Cortes, J.; Vrdoljak, E.; Marschner, N.; Zielinski, C.; Villanueva, C.; Romieu, G.; Lang, I.; Ciruelos, E.; et al. Bevacizumab plus chemotherapy vs. chemotherapy alone as second-line treatment for patients with her2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial. Lancet Oncol. 2014, 15, 1269-1278.
36. Montero, A.J.; Avancha, K.; Gluck, S.; Lopes, G. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res. Treat. 2012, 132, 747-751.
37. Gianni, L.; Romieu, G.H.; Lichinitser, M.; Serrano, S.V.; Mansutti, M.; Pivot, X.; Mariani, P.; Andre, F.; Chan, A.; Lipatov, O.; et al. AVEREL: A randomized phase iii trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for her2-positive locally recurrent/metastatic breast cancer. J. Clin. Oncol. 2013, 31, 1719-1725.
38. Choueiri, T.K.; Mayer, E.L.; Je, Y.; Rosenberg, J.E.; Nguyen, P.L.; Azzi, G.R.; Bellmunt, J.; Burstein, H.J.; Schutz, F.A. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J. Clin. Oncol. 2011, 29, 632-638.
39. Spratlin, J.L.; Cohen, R.B.; Eadens, M.; Gore, L.; Camidge, D.R.; Diab, S.; Leong, S.; O’Bryant, C.; Chow, L.Q.; Serkova, N.J.; et al. Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin g1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 2010, 28, 780-787.
40. Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer. Available online: http://clinicaltrials.gov/ct2/show/NCT00703326 (accessed on 1 December 2014)
41. ClinicalTrial.gov. Available online: http://clinicaltrials.gov (accessed on 25 October 2014).
42. Gradishar, W.J. Sorafenib in locally advanced or metastatic breast cancer. Expert Opin. Investig. Drugs 2012, 21, 1177-1191.
43. Schwartzberg, L.S.; Tauer, K.W.; Hermann, R.C.; Makari-Judson, G.; Isaacs, C.; Beck, J.T.; Kaklamani, V.; Stepanski, E.J.; Rugo, H.S.; Wang, W.; et al. Sorafenib or placebo with either gemcitabine or capecitabine in patients with her-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin. Cancer Res. 2013, 19, 2745-2754.
44. Huober, J.; Fasching, P.A.; Hanusch, C.; Rezai, M.; Eidtmann, H.; Kittel, K.; Hilfrich, J.; Schwedler, K.; Blohmer, J.U.; Tesch, H.; et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (ec) +/- bevacizumab—Results of the randomised geparquinto study (GBG 44). Eur. J. Cancer 2013, 49, 2284-2293.
45. Gampenrieder, S.P.; Romeder, F.; Muss, C.; Pircher, M.; Ressler, S.; Rinnerthaler, G.; Bartsch, R.; Sattlberger, C.; Mlineritsch, B.; Greil, R. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: Results from a retrospective matched-pair analysis. Anticancer Res. 2014, 34, 227-233.
46. Bertolini, F. Response to anti-angiogenesis: An ever changing feature. Breast 2011, 20, S61-S62.
47. Antoniou, A.; Pharoah, P.D.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, A.; et al. Average risks of breast and ovarian cancer associated with brca1 or brca2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72, 1117-1130.
48. Mahdi, K.M.; Nassiri, M.R.; Nasiri, K. Hereditary genes and snps associated with breast cancer. Asian Pac. J. Cancer Prev. 2013, 14, 3403-3409.
49. Nelen, M.R.; Kremer, H.; Konings, I.B.; Schoute, F.; van Essen, A.J.; Koch, R.; Woods, C.G.; Fryns, J.P.; Hamel, B.; Hoefsloot, L.H.; et al. Novel PTEN mutations in patients with cowden disease: Absence of clear genotype-phenotype correlations. Eur. J. Hum. Genet. 1999, 7, 267-273.
50. Schneider, B.P.; Wang, M.; Radovich, M.; Sledge, G.W.; Badve, S.; Thor, A.; Flockhart, D.A.; Hancock, B.; Davidson, N.; Gralow, J.; et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 2008, 26, 4672-4678.
51. Miles, D.W.; Chan, A.; Dirix, L.Y.; Cortes, J.; Pivot, X.; Tomczak, P.; Delozier, T.; Sohn, J.H.; Provencher, L.; Puglisi, F.; et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010, 28, 3239-3247.
52. Miles, D.W.; de Haas, S.L.; Dirix, L.Y.; Romieu, G.; Chan, A.; Pivot, X.; Tomczak, P.; Provencher, L.; Cortes, J.; Delmar, P.R.; et al. Biomarker results from the avado phase 3 trial of first-line bevacizumab plus docetaxel for her2-negative metastatic breast cancer. Br. J. Cancer 2013, 108, 1052-1060.
53. Keyhani, E.; Muhammadnejad, A.; Behjati, F.; Sirati, F.; Khodadadi, F.; Karimlou, M.; Moghaddam, F.A.; Pazhoomand, R. Angiogenesis markers in breast cancer—Potentially useful tools for priority setting of anti-angiogenic agents. Asian Pac. J. Cancer Prev. 2013, 14, 7651-7656.
54. Jubb, A.M.; Miller, K.D.; Rugo, H.S.; Harris, A.L.; Chen, D.; Reimann, J.D.; Cobleigh, M.A.; Schmidt, M.; Langmuir, V.K.; Hillan, K.J.; et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin. Cancer Res. 2011, 17, 372-381.
55. Ohtsu, A.; Shah, M.A.; van Cutsem, E.; Rha, S.Y.; Sawaki, A.; Park, S.R.; Lim, H.Y.; Yamada, Y.; Wu, J.; Langer, B.; et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 2011, 29, 3968-3976.
56. Saltz, L.B.; Clarke, S.; Diaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T.S.; Rivera, F.; et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J. Clin. Oncol. 2008, 26, 2013-2019.
57. Errico, A. Combining bevacizumab with chemotherapy—From maintenance to second-line treatment. Nat. Rev. Clin. Oncol. 2014, doi:10.1038/nrclinonc.2014.179.
58. Pepin, F.; Bertos, N.; Laferriere, J.; Sadekova, S.; Souleimanova, M.; Zhao, H.; Finak, G.; Meterissian, S.; Hallett, M.T.; Park, M. Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3246.
59. Wang, N.; Wang, Z.Y.; Mo, S.L.; Loo, T.Y.; Wang, D.M.; Luo, H.B.; Yang, D.P.; Chen, Y.L.; Shen, J.G.; Chen, J.P. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via vegfr-2 signaling pathway in breast cancer. Breast Cancer Res. Treat. 2012, 134, 943-955.
60. Purdue, M.P.; Johansson, M.; Zelenika, D.; Toro, J.R.; Scelo, G.; Moore, L.E.; Prokhortchouk, E.; Wu, X.; Kiemeney, L.A.; Gaborieau, V.; et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat. Genet. 2011, 43, 60-65.
61. Sledge, G.W. Anti-vascular endothelial growth factor therapy in breast cancer: Game over? J. Clin. Oncol. 2014, doi:10.1200/JCO.2014.58.1298.
62. De Luca, A.; Lamura, L.; Gallo, M.; Maffia, V.; Normanno, N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J. Cell Biochem. 2012, 113, 3363-3370.